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Abstract
Introduction: The radiochemical purity (RCP) of technetium-99m labelled
radiopharmaceuticals (RP) is important to ensure optimal scintigraphic image quality.
In low-income settings, it may not be possible to use compendial analytical methods
or expensive equipment for radiochemical purity analysis. All radiochemical analysis
methods should however be validated against compendial or otherwise proven
methods. To ensure the efficacy of RP prepared at Yaoundé General Hospital (YGH)
Cameroon, this study cross-validated a cost-effective routine chromatographic
method using a simple survey meter technique. A GMP-compliant method used at
the University Medical Center Groningen (UMCG), the Netherlands was used as the
comparator.
Methods: Sestamibi, HMDP and DMSA kits currently used at YGH were reconstituted
at UMCG with about 2000 MBq of freshly eluted sodium pertechnetate as described
by the manufacturer, and spiked with eluate of the same generator to obtain a
range of impurity concentrations. Samples of technetium-99m RP were spotted on
1 × 10 cm iTLC-SG strips and developed in appropriate mobile phases. Each strip was
first scanned on the chromatogram-scanner used at the UMCG (standard method),
and immediately thereafter the strip was cut in two pieces and radioactivity from
each portion was counted with a small survey meter from YGH. The percentage RCP
for each TLC strip was calculated using both counting methods. Internationally
recommended validation parameters and acceptance criteria were used. Student’s
paired t-test or ANOVA were used with ‘no significant difference’ designated at a
95% confidence-interval (P ≥ 0.05). Linearity of the survey meter was determined for
Tc-99m. Readings obtained with the survey meter were also plotted against the
scanner results.
Results and discussion: The proposed method proved to be accurate (CV of mean
RCP < 2), precise (RSD < 2%), linear (slope close to 1, r2≥ 0.99) within the RCP range
of approximately 80% to 100%, and robust (P > 0.05). LOD and LOQ were determined
for the survey meter. Specificity depends on chemical separation. As we were
validating the suitability of a method to quantify radioactivity, specificity was not
included in the validation parameters.
(Continued on next page)
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Conclusion: The proposed method compared well with the standard method and is
suitable as a reliable low cost method for limited resource settings.
Keywords: Radiochemical method, Quality control, Developing countries
Introduction
Importance of method validation
Nuclear Medicine needs optimal quality radiopharmaceuticals for accurate diagnosis
and therapy of diseases (IAEA 2008; Dondi et al. 2011). As the use of Nuclear Medicine
increases in developing countries, including those in sub-Saharan Africa, so does the
need for radiopharmaceuticals. With the increasing demand for radiopharmaceuticals,
it is of paramount importance to ensure that only safe and effective products are ad-
ministered to patients (IAEA 2016). Even though most radiopharmaceuticals in sub-
Saharan Africa are prepared in small scale units, quality assurance programs should be
implemented (Elsinga et al. 2010). Internationally, guidelines for Good Radiopharmacy
Practice recommend that only validated analytical methods should be used to evaluate
product quality before patient use. Quality assurance (QA) in the production of radio-
pharmaceuticals ensures that they are of sufficient quality for their intended purpose; it
reduces the possibility of producing substandard products by adhering to specified pro-
cedures and protocols (Vincenti et al. 2016). Analytical Quality Control (QC) methods
form part of quality assurance, helping to assess the quality of the product. According
to Ajay et al., validation of analytical methods provides evidence that the method is
suitable for it intended use, and thus helps to ensure provision of safe and effective final
products (Ajay and Rohit 2012). The consequence of using unvalidated non-
compendial methods could result in the administration of unknown substances, poor
quality images and/or an unnecessary radiation exposure of patients (Amin et al. 2011;
Vincenti et al. 2016).
The principle of validation of quantitative analytical methods
Validation of an analytical procedure is the process to ensure that the performance
characteristics of the procedure adopted in a particular laboratory meet the require-
ments for the intended analytical application (USP 37 < 1225> 2008). In radiopharmacy,
one of the most frequently used analytical criteria is radiochemical purity (RCP) of the
product. The radiochemical purity of a preparation is the fraction of the total radio-
activity in the desired chemical form of the radiopharmaceutical. During the labelling
process, radiochemical impurities may be present as a result of incomplete radiolabel-
ling or decomposition products due to the presence of oxidizing or reducing agents, ra-
diolysis or change of temperature and pH (Saha 2010; Millar et al. 2009; Loveless 2009;
Mambilima 2016).
RCP can be assessed by various analytical techniques, for example paper, thin layer,
or liquid chromatography and electrophoresis. Radiochromatography involves the sep-
aration of components in solution (depending on their affinity with the chromatog-
raphy materials), and the measurement of the distribution of radioactivity on the
chromatogram (Saha 2010).
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International guidelines describe validation parameters and acceptance criteria for
validation of analytical methods, including accuracy, precision, intermediate precision,
linearity, range, specificity, robustness, detection limit and quantitation limit (USP 37 <
1225> 2008; EDQM 2018; Krause 2003).
Validation studies of radiochemical analysis methods in literature
In the literature, analytical methods’ performance characteristics for both SPECT (Sin-
gle Photon Emission Computed Tomography) and PET (Positron Emission Tomog-
raphy) radiopharmaceuticals differ slightly from one study to another. The parameters
recommended by the ICH (International Council for Harmonisation 2006), namely ac-
curacy, precision, linearity and range, specificity, robustness and limit of quantitation
(LOQ), are frequently used, especially for HPLC (High-Performance Liquid Chroma-
tography) methods. However, it should be noted that radio-TLC and radio-HPLC ex-
press RCP as a ratio between counts or areas, without requiring absolute quantitative
measurement of either the product or impurities. In this scenario, accuracy and LOQ,
which both address quantitative measurement, may not be relevant for radio-HPLC or
radio-TLC (Todde et al. 2014), or may need a different approach than in the case of
chemical analyses.
Mihon et al. mention the ICH parameters for the HPLC determination of identity
and RCP of [18F]NaF (Mihon et al. 2016). Leonardi et al. use these parameters in the
validation of a paper chromatography method as an alternative for determination of the
RCP of [18F]NaF (Leonardi et al. 2012). Seetharaman et al. (2006) validate their simpli-
fied solid phase extraction method for determining the RCP of [99mTc]Tc-MAG3 by de-
termining specificity, linearity, and robustness. They compare their method against a
standard method to evaluate accuracy and precision. Acceptance criteria for analytical
method validation may require adjustments according to the type of equipment: radio-
HPLC, radio-UPLC (Ultra Performance Liquid Chromatography), radio-TLC (Thin
Layer Chromatography), or gamma spectrometry (Todde et al. 2017). Besides perform-
ance characteristics related to the method of analysis, analytical method validation
could differ regarding experimental details such as mobile phase, stationary phase, flow
rate, and wavelength of UV detectors (Todde et al. 2017).
Several studies describe the development of alternative chromatography procedures
to replace ‘gold-standard’ methods for reasons including simplified technical handling
and more rapid processing times. Faria et al. in 2015 studied an alternative chromato-
graphic system for the quality control of MIBI where they evaluated different solvents
to optimize separation efficiency, reproducibility and analysis time (Faria et al. 2015).
This was, however, not a full validation study as defined in documents of normative
character: ISO (International Organization for Standardization), ICH, FDA (Food and
Drug Administration) (Krause 2002; USP 37 < 1225> 2008), with performance charac-
teristics evaluated against acceptance criteria from references. Luebke et al. (2000) also
evaluated an alternative testing method for the radiochemical purity determination of
MIBI but did not include all parameters recommended in guidelines (USP 37 < 1225>
2008). Something similar was done for 99mTc-Annexin A5, using a binding assay in-
stead of radio-TLC for determination of radiochemical purity as a release method
(Boersma et al. 2004).
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A variety of methods for quantification of distribution of radioactivity on radio-TLC
plates are described in literature. Decristoforo and Zolle provide an overview of seven
methods used for 99mTc radiopharmaceuticals, including cutting and counting in a
scintillation counter, chromatogram scanning, analysis by linear analyzer and
phosphor-imager autoradiography (Decristoforo and Zolle 2007). The methods differ
regarding sensitivity, resolution and linearity, but differences in time required per ana-
lysis and the cost of equipment of each of these methods are considerable, making their
adoption in resource-poor developing countries challenging. At Yaoundé General Hos-
pital in Cameroon (YGH) there is no chromatogram scanner or more advanced equipment
with which the distribution of radioactivity or chromatograms of radiopharmaceuticals can
be analyzed. An alternative method was therefore sought, namely counting sections of the
chromatography strips corresponding to the distribution of the different radiochemical spe-
cies with a contamination monitor available in the Nuclear Medicine department at YGH.
Prior to employing it in daily practice, this proposed method had to be validated. The work
described herein was performed to validate a cost-effective method for quantifying the dis-
tribution of radioactivity on chromatography strips using a RadEye 20 contamination moni-
tor (available at YGH), and comparing it to the already validated method routinely used at
the UMCG in the Netherlands.
Materials and methods
Materials for product preparation and chromatography
All experiments were performed at the UMCG radiopharmacy in the Netherlands.
SPECT radiopharmaceutical kits Stamicis (2-methoxyisobutylisonitrile: MIBI), Osteocis
(hydroxymethylene diphosphonate: HMDP), and Renocis (dimercaptosuccinic acid:
DMSA), all from Curium, France, currently used for nuclear medicine imaging at YGH,
were used for this study. Technetium-99m (99mTc) was obtained from an Ultra-
Technekow generator (Mallinckrodt Medical BV, Netherlands). TLC scanning was per-
formed using a VCS-103 scanner (Comecer S.P.A., Italy) used at UMCG. A calibrated
RadEye B20 multipurpose counter (Thermo Fisher Scientific Messtechnik, Germany)
was brought from YGH and used at UMCG for the comparative experiments. Chroma-
tography was done using iTLC-SG sheets (Varian) with butan-2-one (methyl ethyl ke-
tone) (Fluka) or 0.9% saline solution (B Braun) as mobile phases.
Sample preparation
Freshly eluted technetium-99m sodium pertechnetate ([99mTc]NaTcO4) was used to
prepare each radiopharmaceutical following the kit manufacturer’s instructions or sum-
mary of product characteristics (Osteocis 3 mg 2016; Renocis 2016; Stamicis 2016).
Technetium-99 m-radiopharmaceutical kits ([99mTc]Tc-HMDP, [99mTc]Tc-MIBI and
[99mTc]Tc-DMSA) each from a single lot were prepared and spiked with adequate
quantities of sodium pertechnetate in order to reach different RCP values to evaluate.
The radiochemical purity we aimed for in the spiked products ranged between approxi-
mately 80% and 100%.
Each of the cold kits included in this study was reconstituted with about 2000MBq
[99mTc]NaTcO4
− read with the dose calibrator (VDC 404 Veenstra, Joure).
Ekoume et al. EJNMMI Radiopharmacy and Chemistry             (2020) 5:9 Page 4 of 14
Chromatography of radiopharmaceuticals
A drop of the same Tc-99 m eluate used for kit reconstitution (and to spike the radio-
pharmaceuticals) was used to run a control analysis under the same conditions as those
of the radiopharmaceutical samples.
5 μl of [99mTc]Tc-RP samples was spotted on 10 cm iTLC-SG strips. For HMDP and
DMSA, the strips were then developed in methyl ethyl ketone as mobile phase, and for
MIBI, the strips were developed in NaCl 0.9%. Under these conditions, [99mTc]Tc-
HMDP, [99mTc]Tc-DMSA and [99mTc]Tc-MIBI remained at the origin and the impur-
ity (pertechnetate) migrated with the solvent front. After developing, each strip was first
scanned on the Veenstra VCS-203 TLC scanner using a low energy collimator with en-
ergy window range from 135 to 145 keV. The scan time was 60 s and background
counts were subtracted. Within 5 min thereafter the strip was cut in 2 pieces at 4 cm
from the origin. The radioactivity from each portion of the strip was counted for 1 min
with the RadEye B 20 counter which is a multipurpose survey meter with gamma en-
ergy range from 17 keV to 3MeV (measurement range from 0 to 500 kcps). Each strip
was placed flat in the bottom of a 10 cm deep container and the counter placed at the
top of the container to ensure counting geometry was the same for all samples. Each
count rate reading was recorded with background count rate subtracted. From these
values, the percentage of radiochemical purity of each strip was calculated.
Validation studies
The methods for validation of determination of RCP of the current study followed
international guidelines from the United States Pharmacopoeia (USP 37 < 1225> 2008),
and the EDQM Guide (2018). Parameters used include accuracy, precision repeatability,
intermediate precision, linearity, assay range, method robustness, limit of detection
(LOD) and limit of quantitation (LOQ). Note that specificity of chromatographic
methods depends on the chemical separation of compound and impurities. In the valid-
ation of the radioactive counting method, this parameter is thus not relevant.
Accuracy
Mean RCP values from three replicates of each sample were determined as well as the
coefficient of variation (CV). The accuracy criteria for the radiopharmaceutical compo-
nent are met when the mean of the standard method differed by not more than 1.5%
from the mean value of the proposed method.
Repeatability
The repeatability precision was assessed with five replicates of a spiked sample and the
relative standard deviation (RSD) was calculated.
Intermediate precision
The intermediate precision was determined by repeating at two different time points
(3 h between the tests), the chromatography of 5 replicates of spiked samples per-
formed by 2 different operators, quantifying distribution of activity on the strips using
the two different counting systems. Mean RCP values and RSD were calculated. The
statistical evaluation by ANOVA of the complete data set where results are grouped by
Ekoume et al. EJNMMI Radiopharmacy and Chemistry             (2020) 5:9 Page 5 of 14
each operator, each time point and instrument were analyzed with acceptance criteria
stating no significant difference at 95% CI (P ≥ 0.05).
Linearity
To test the linearity, the response of the survey meter to Tc-99 m was evaluated. A 5
MBq point source of Tc-99 m was repeatedly counted over a period of 27 h. The mea-
sured count rate was plotted against the calculated activity of the point source. In
addition, chromatography of three replicates from each spiked sample were performed
and the chromatograms were read with both the scanner and the counter for RCP de-
termination as described above. The linearity results include the equation from the lin-
ear regression obtained from a plot of % RCP determined with the counter (proposed
method) against the RCP values determined with the scanner (the validated control
method of the GMP compliant radiopharmacy), its slope, the correlation coefficient
and Y intercept. As acceptance criteria, the slope should be close to 1, and r2 ≥ 0.99.
Robustness
The robustness of the chromatography counting method with the RadEye B20 counter
was evaluated by comparing the variation of count rates of five replicates of a spiked sam-
ple of MIBI. The pairs of strip sections were read with the counter in slightly different po-
sitions, i.e. one in the normal reading position and the other section with the counter at
an angle differing 5° from the normal position (Fig. 1). Mean RCP from each set of counts
and RSD were calculated. ANOVA was used to check if there were any significant differ-
ences between the groups. Acceptance criteria are RSD < 5% and P ≥ 0.05.
Limit of detection and limit and quantitation
The limit of detection of the RadEye B20 counter was evaluated by counting a blank
(strip with no analyte) twenty times with the counter and calculating the mean of blank
counts plus 3 times the standard deviation of the blank. The limit of quantitation was
calculated as the mean of blank counts plus 10 times the standard deviation of the
blank (EDQM 2018).
Results
Complete results are shown in tables and figures.
Fig. 1 Illustration of the robustness test methodology (reading with counter at normal position and at
5° angle)
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Accuracy
Samples with RCP between 78% and 100%, with activities between 2 and 3MBq were
spotted on the TLC plates. The mean RCP of triplicate analyses at each sample RCP
level from reading of both instruments for the 3 radiopharmaceuticals are shown in
Table 1.
Repeatability precision
The RSD for 5 replicates of spiked samples for the three products from both devices
varied between 0.6% and 1.7%. For the impurity values, the RSD ranged from 0.5 to 6.1
(Table 2).
Intermediate precision
Results from the method performed by different operators at different time points for
the three products gave RCP range from 78.3% to 83.4%, impurity range from 16.8% to
23.3%, highest RSD value 6.1 with P values between 0.2 and 11.8 (ANOVA) (Tables 3
and 4).
Linearity
The response of the counter to Tc-99m activity ranging from 0.2MBq to 5MBq is
shown in Fig. 2. The regression curves for values obtained with the survey meter
against the scanner results for each of the radiopharmaceuticals are shown in Fig. 3. All
values of r2 were above 0.99 and all slopes close to 1.
Robustness
Results from 5 replicates of a spiked MIBI sample with one part counted with slight de-
viation in counter position compared very well with those obtained with the counter in
the normal position Results are given in Table 5.







Scanner Counter Diff Scanner Counter Diff Scanner Counter Diff
99.7 ± 0.1 99.5 ± 0.1 0.2 99.3 ± 0.4 99.2 ± 0.1 0.1 99.9 ± 0.0 99.4 ± 0.2 0.5
99.2 ± 1.1 99.2 ± 0.1 0.0 98.5 ± 0.4 98.8 ± 0.7 0.3 97.8 ± 1.0 98.0 ± 1.0 0.2
92.0 ± 1.7 91.8 ± 1.1 0.2 91.3 ± 3.7 90.6 ± 3.0 0.7 96.6 ± 1.0 95.2 ± 0.9 1.4
87.9 ± 1.6 88.1 ± 1.3 0.2 84.7 ± 0.6 86.0 ± 2.0 1.3 87.1 ± 1.2 86.3 ± 1.1 0.8
82.9 ± 0.8 81.9 ± 1.5 1.0 78.9 ± 5.0 78.4 ± 7.0 0.5 82.0 ± 0.6 82.1 ± 0.8 0.1
N = 3; Diff: difference between RCP from scanner and counter for each product; CV coefficient of variation.
Table 2 Repeatability precision of the proposed method for the 3 compounds
DMSA
% RCP Mean ± RSD
MIBI
% RCP Mean ± RSD
HMDP
% RCP Mean ± RSD
Scanner Counter Scanner Counter Scanner Counter
RCP 83.1 ± 0.6 83.4 ± 0.8 79.7 ± 1.7 80.9 ± 1.4 82. 0 ± 0.7 82.0 ± 0.6
Impurity 16.8 ± 3.6 16.6 ± 4.2 19.1 ± 4.3 19.0 ± 6.1 18. 0 ± 3.1 17.9 ± 0.5
n = 5; RSD relative standard deviation.
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Limit of detection and limit of quantitation
The results from twenty counts of the blank sample (n = 20) gave 0.6 counts per second
as a mean value of the blank with standard deviation of 0.1, for a LOD value of 0.9
counts per second. The calculated LOQ was 1.6 counts per second. Based on the lin-
earity curve this represents approximately 0.06MBq.
Discussion
The importance of method validation
Recommended analytical methods are supplied with package inserts from radiopharma-
ceutical kits and by pharmacopoeia monographs. In radiopharmacies with limited fund-
ing, it may be difficult to follow the recommended analytical methods due to lack of
adequate equipment and limited availability of consumables. Other disadvantages of many
of the recommended methods include the time required to complete the tests, which
Table 3 Intermediate Precision results: Different Operators (n = 5, acceptance criteria P ≥ 0.05)
Spiked samples Device Operator 1
Mean %RCP ± RSD
Operator 2
Mean %RCP ± RSD
ANOVA (P)
DMSA Scanner RCP 83.1 ± 0.6 81.6 ± 0.8 3.1
Scanner Imp 16.8 ± 3.6 18.1 ± 2.9 0.7
Counter RCP 83.4 ± 0.8 82.5 ± 0.7 0.5
Counter Imp 16.6 ± 4.2 17.4 ± 3.7 0.5
MIBI Scanner RCP 79.7 ± 1.7 79.8 ± 1.0 1.1
Scanner Imp 19.1 ± 4.3 19.6 ± 4.9 0.6
Counter RCP 80.9 ± 1.4 80.3 ± 0.7 0.8
Counter Imp 19.0 ± 6.1 19.6 ± 2.9 0.8
HMDP Scanner RCP 82.0 ± 0.7 81.6 ± 0.9 0.4
Scanner Imp 18.0 ± 3.1 18.0 ± 4.7 0.4
Counter RCP 82.4 ± 0.6 82.3 ± 0.5 0.2
Counter Imp 17.9 ± 0.5 17.6 ± 3.1 0.2
Table 4 Intermediate Precision results: Effect of Time (acceptance criteria ANOVA P≥ 0.05)
Spiked samples Device Time 1 mean %RCP ± RSD Time 2 mean
%RCP ± RSD
P
DMSA Scanner RCP 83.1 ± 0.6 78.3 ± 0.8 5.8
Scanner Imp 18.8 ± 3.6 20.1 ± 4.5 3.2
Counter RCP 83.4 ± 0.8 76.7 ± 1.4 11.8
Counter Imp 16.6 ± 4.2 23.3 ± 4.9 11.8
MIBI Scanner RCP 79.7 ± 1.7 77.2 ± 1.1 2.6
Scanner Imp 19.1 ± 4.3 22.6 ± 4.5 3.4
Counter RCP 80.9 ± 1.4 78.2 ± 0.6 2.5
Counter Imp 19.0 ± 6.1 21.7 ± 2.3 2.5
HMDP Scanner RCP 82.0 ± 0.7 79.1 ± 1.1 2.5
Scanner Imp 18.0 ± 3.1 19.9 ± 4.4 1.3
Counter RCP 82.0 ± 0.6 78.3 ± 0.9 3.8
Counter Imp 17.9 ± 0.5 21.6 ± 3.4 3.8
Note: Same operator at different times; n = 5; Imp: impurity
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delays administration of the short-lived products to patients, and use of relatively large
volumes of solvents when solid phase extraction (SPE) or HPLC are used (Seetharaman
et al. 2004). Thus there is a clear need for practical, simple, faster (Hammes et al. 2004;
Mihon et al. 2016) and low cost methods. Any alternative methods should be validated
prior to use (Leonardi et al. 2012).
The current study describes the validation of a cost-effective quantification method
for instant thin layer radiochromatography strips using a counting system (RadEye 20)
available at YGH, cross-validated with a routine method used at the GMP compliant
radiopharmacy at UMCG.
In the current work, the validation parameters prescribed by the ICH (USP 37<
1225> 2008), i.e. linearity, precision, intermediate precision, accuracy, assay range,
method robustness, limit of detection and limit of quantitation were all included for
each of 3 SPECT radiopharmaceuticals commonly used at YGH (HMDP, DMSA,
MIBI).
Standards and sampling
In validation of analytical methods, reference standards are generally used for com-
parison purpose. Certified reference standards for 99mTc impurities do not exist in
the radiopharmaceutical industry due to the short half-life and short shelf life of
the radiolabeled complexes as well as absence of a stable isotope of 99mTc. In our
study, samples containing varying concentrations of 99mTc-RP were obtained by
spiking with adequate quantities of sodium pertechnetate and measured with a vali-
dated method for comparison with the proposed alternative counting method.
Seetharaman et al. used a similar approach to determine linearity of their method
(Seetharaman et al. 2006).
Table 5 Robustness of the counter
%RCP Mean ± RSD %RCP Mean ± RSD %RCP Mean ± RSD
Change counter at normal
position for both parts
counter tilted 5° for the strip
section containing the impurity
counter tilted 5° for the strip section
with the bound compound
MIBI
(n = 5)
91.5 ± 1.0 91.8 ± 2.6 (P = 2.9*) 91.9 ± 2.3 (P = 2.4*)
*P values for ANOVA of the respective RCP compared to RCP obtained with the counter in the normal position
Fig. 2 Response of the counter for Tc-99m activity
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Accuracy
Accuracy can be described as being as near as possible to the expected value. For the
experiments in this study, we used a similar approach to Mambilima, comparing differ-
ences between values from standard to proposed methods (Mambilima 2016). We cal-
culated the difference between RCP mean value of the standard method and the
method of study for the three radiopharmaceuticals at each RCP level after spiking with
pertechnetate. All differences in RCP were smaller than 1.5%, confirming the method
of study met the accuracy criteria. Different approaches have been used in the litera-
ture. Mihon et al. used the percentage recovery within a predetermined specified range
to demonstrate the accuracy of the method he proposed (Mihon et al. 2016), while Leo-
nardi et al. in 2012 used the RSD value of the mean percentage recovery to validate the
accuracy of their method (Leonardi et al. 2012). As we used a TLC method here, the
recovery parameter is not relevant, because all used sample material will remain
present during the analytical procedure, which is not the case for methods using chro-
matography columns like HLPC.
In this study HMDP, DMSA and MIBI accuracy analysis met the acceptance criteria
at the five RCP levels tested. Thus for the three radiopharmaceuticals the comparison
of respective results obtained from the two counting systems is good. This indicates
that the proposed counting method using the RadEye B20 counter is demonstrated to
be as good as the Veenstra VCS-203 TLC scanner.
Precision
Precision can be defined as the closeness of measurements to each other. In contrast
with accuracy, no relation is investigated between the result and the expected result, or
Fig. 3 Linearity of the proposed method for the 3 products, counter response compared with RCP values
determined with the scanner
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true value. The validation of precision in the current work was twofold: firstly, we eval-
uated repeatability with five replicates of a spiked sample for each product. The RSD
values of the impurities were much lower than acceptance value 15%. It should be
noted that for RCP measurements (i.e. the active pharmaceutical ingredient or radio-
pharmaceutical compound) such a high RSD value is not acceptable. The proposed
method using the RadEye B20 counter is regarded as precise. Secondly, we did inter-
mediate precision tests by the evaluation of the method using different operators, and
analysis at different time points, and found no significant differences. Seetharaman used
a similar approach to compare a standard ITLC method previously developed by Chen
et al. (Chen et al. 1993) to a simpler method developed using a solid phase extraction
cartridge (Seetharaman et al. 2006). Even though our survey meter is a relatively simple
piece of equipment, these results encourage us to advocate the use of the RadEye B20
counter, especially in a low-cost setting.
Linearity and range
The range of radiochemical purity between approximately 80% and 100% used in the
study was chosen in order to include RCP values recommended by manufactures for
patient use (95% to 100%) and to be in accordance with ICH and pharmacopeia recom-
mended minimum of five concentrations in the range from 80% to 120% for finished
products or assays of drug substances (USP 37 < 1225> 2008). Our samples contained
approximately 2 to 3MBq/5 μl.
To prove linearity, the analytical method should exhibit proportionality to the con-
centration of the analyte at the chosen range; r2 should be determined as well as the
equation and slope of the regression line. We studied the response of the RadEye B20
counter to Tc-99m radioactivity. Linearity was demonstrated between 0.2 and 5MBq.
As the maximal amount of counts expected for QC strips is much lower than the max-
imum of the range of the RadEye B20 counter, which can count up to 500 kcps accord-
ing to its specifications, we expect no dead time problems using our method.
Robustness
Parameters such as mobile phase composition, and ambient temperature influencing
the stationary and mobile phase flow are typically used to evaluate robustness, espe-
cially for HPLC methods (Mihon et al. 2016). In this work, we evaluated the suitability
of a counting system, which is independent of chemical separation. Careless positioning
of the survey meter might lead to differences in counting geometry between the two
parts of a chromatography strip. Based on the possibility of slight differences in count-
ing position of the counter, the robustness of the counting system was checked by com-
paring counts with a correctly positioned counter against a slightly tilted counter. No
significant differences in count rates were demonstrated, so the method could with-
stand at least a small variation in positioning the counter.
Limit of detection and limit of quantitation
Some authors argue that limits of detection and of quantification are not required for
RCP determination with thin layer radiochromatography. Todde et al. indicate that
LOQ as usually included in validation studies, may not be relevant where the RCP is
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determined as a ratio between areas or counts, and no absolute quantitative measure-
ment is required to be performed (Todde et al. 2014). Seetharaman et al. (2006) state
that determination of LOD and LOQ can be omitted as only products with RCP values
higher than 90% are used clinically. It is however important to know if the counting de-
vice is able to distinguish the lowest expected or clinically meaningful impurity activity
from background counts.
Tc-99 m products are usually required to have a RCP of 90 or 95%, i.e. not more than
5% of impurities may be present. Exact quantification of impurities larger than 2% may
not be mandatory, as it will not affect the acceptance of the product. Calculated from
our linearity measurements, 2% of our 5MBq samples would give a count rate of ap-
proximately 80 cps, or 50 times the LOQ of the survey meter. Looking at the calibra-
tion curve, uncertainties are present in the lower range of radioactivity. We think that
small impurities will rather be overestimated than underestimated. Thus the survey
meter can be used, but care should be taken not to use very low amounts of Tc-99 m,
as impurities might then be below the LOQ.
Specificity
The specificity of chromatographic methods depends on the separation of different
chemical entities, e.g. the active pharmaceutical ingredient and any impurities. For
HPLC, this means that the peaks of the different chemical entities should be clearly
separated. In our evaluation of the method of quantification of the distribution of
radioactivity, the chemical separation was done with thin layer chromatography, and
the same strip was then used for both counting methods. We therefore did not include
specificty in our validation. For the same reason we also did not test for impurities
other than pertechnetate.
Summary
Guidelines for analytical method validation as presented by international regulatory
bodies and national authorities (e.g. ICH, FDA) and described in available literature,
usually do not provide much information for radioanalytical methods such as radio-
TLC (ICH Q2R1, EMEA 2006). A notable exception is the Guide published by the
EDQM in 2018 which does address validation of analytical methods for radiopharma-
ceuticals. Using internationally recommended parameters, we validated our proposed
method by comparison with a validated method routinely used in a GMP unit.
Limitations of this study include the non-availability of reference standards for Tc-99
m labelled compounds since there are no stable isotopes of technetium (Todde et al.
2014). The range over which the linearity curve for the survey meter was determined,
includes typical activities for sample drops used for RCP analysis of Tc-99m radiophar-
maceuticals with iTLC, but should be extended at the lower end to unequivocally in-
clude activities expected in impurities representing 0.5% of the sample. Furthermore
the linearity measurement with the survey meter for Tc-99m should be extended to in-
clude higher activities if radiopharmaceuticals with higher radioactivity concentrations
are to be analysed.
In validation studies, sample preparation should be done very carefully, and effects
like possible adhesion of impurities to containers used in preparing samples should be
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considered in the design of the tests. Furthermore, spiking samples with pertechnetate
may result in additional labeling of the Tc-99m-radiopharmaceutical, which may cause
an additional uncertainty in the outcome of the experiments.
Conclusion
Compared to the standard method, our alternative method was linear, accurate, specific
in the range of product concentrations internationally recommended for patients, pre-
cise, and robust. The value of the successful validation of the proposed method is two-
fold: Firstly, it has increased the awareness of the importance of validation among staff
in our unit, and secondly, a cost-effective method is now available and can be used in
any other low income Nuclear Medicine units.
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